Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 30Terminated 5Withdrawn 3Unknown 3Recruiting 3Not yet recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Dermatologic 1

Conditions

Melanoma 5Thyroid Neoplasms 3Neoplasms 3Colorectal Neoplasms 2Solid Tumor 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1

Interventions

Exercise 19Drug Therapy 18pembrolizumab 13Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Paclitaxel 9Dexamethasone 9Nivolumab 8Standard of Care 7Oxaliplatin 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Control Groups 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Neoplasms × trametinib × Clear all
NCT05876806 2023-11-30

Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

Seoul St. Mary's Hospital

Phase 2 Unknown
30 enrolled
Tumor-Agnostic

Neoplasms

NCT02858921 2023-08-30

Neo Trio

Melanoma Institute Australia

Phase 2 Unknown
60 enrolled
Dermatologic

Melanoma, Neoplasms

NCT03543306 2018-06-01

Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

Asan Medical Center

Phase 2 Unknown
27 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡